insulin + liraglutide

This investigational combination therapy consists of insulin and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being studied by the Albert Einstein College of Medicine for the treatment of type 1 diabetes mellitus. The regimen involves using liraglutide as an adjunctive therapy to insulin delivered through a closed-loop insulin delivery system (artificial pancreas). Liraglutide works by slowing gastric emptying and suppressing glucagon secretion, which helps to flatten postprandial glucose peaks that are often difficult to manage with insulin alone in type 1 diabetes. Clinical trials have focused on whether this combination can improve glycemic control and minimize postprandial hyperglycemia compared to standard closed-loop insulin monotherapy.

Other names

adjuvant liraglutide and insulinliraglutide with closed loop insulin